Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.

EBioMedicine - 1 Aug 2016

Benamar Mouadh, Guessous Fadila, Du Kangping, Corbett Patrick, Obeid Joseph, Gioeli Daniel, Slingluff Craig L, Abbas Tarek

Abstract excerpt

The cullin-based CRL4-CDT2 ubiquitin ligase is emerging as a master regulator of cell proliferation. CRL4-CDT2 prevents re-initiation of DNA replication during the same cell cycle "rereplication" through targeted degradation of CDT1, SET8 and p21 during S-phase of the cell cycle. We show that CDT2 is overexpressed in cutaneous melanoma and predicts poor overall and disease-free survival. CDT2 ablation inhibited a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Cyclopentanes

Share to Histone-Lysine N-Methyltransferase

Share to Protein Stability

Share to Ubiquitination

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27333051
DOI: 10.1016/j.ebiom.2016.06.023
PMCID: PMC5006603

Genes

BRAF
CDT1
NEDD8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.PMID 27333051Read ↗

PSMD14 drives melanoma cell survival and MAPK inhibitor resistance through histone H2A deubiquitinationSemantic proximity Read ↗

SCFβ-TRCP promotes cell growth by targeting PR-Set7/Set8 for degradationSemantic proximity Read ↗

Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma PathogenesisSemantic proximity Read ↗

CRL4<sup>Cdt2</sup>Semantic proximity Read ↗

Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting TherapiesSemantic proximity Read ↗

The c-Cbl-mediated non-canonical TGFBR2 neddylation drives BRAF V600E melanoma metastasisSemantic proximity Read ↗

USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axisSemantic proximity Read ↗

CDK9 recruits HUWE1 E3 ligase to degrade RARα in a kinase independent manner and offers therapeutic opportunities for cutaneous T-cell lymphomaSemantic proximity Read ↗

Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapySemantic proximity Read ↗

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and TherapySemantic proximity Read ↗

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for MelanomaSemantic proximity Read ↗

Up‐regulated deubiquitinase USP 4 plays an oncogenic role in melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.